For the quarter ending 2026-03-31, SABS had $10,017,044 increase in cash & cash equivalents over the period. -$15,254,387 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,868,885 | -16,860,743 | 30,134,426 | - |
| Depreciation and amortization | 730,965 | 741,593 | 743,764 | 1,509,406 |
| Amortization of finance right-of-use assets | 21,705 | 21,706 | 21,705 | 43,412 |
| Stock-based compensation expense | 5,459,911 | 3,169,734 | 800,764 | 1,240,149 |
| Gain on the sale of equipment | 2,217 | - | - | - |
| Net realized and unrealized (gain) loss on equity securities | -9,587 | 9,929 | 62,829 | 1,209 |
| Net realized gain on debt securities | 47,089 | - | - | - |
| Changes in fair value of warrant liabilities | 482,474 | 3,253,435 | -66,007,621 | - |
| Accretion of discounts on investments | -10,075 | 36,864 | 23,681 | 28,086 |
| Write-off of deferred issuance costs | - | 261,105 | - | - |
| Gain in early termination of lease liability | 7,042 | - | - | - |
| Accrued interest receivable | 608,280 | 386,827 | 559,954 | -54,955 |
| Prepaid expenses and other current assets | 297,263 | 6,863,069 | -2,131,089 | 553,279 |
| Operating lease right-of-use assets and liabilities, net | 74,224 | -3,861 | -4,124 | -59,435 |
| Accounts payable | 114,119 | 324,527 | 335,924 | 822,342 |
| Accrued expense and other current liabilities | -1,194,966 | -394,856 | -287,490 | 1,623,870 |
| Net cash used in operating activities | -14,271,130 | -16,776,327 | -13,050,023 | -14,948,761 |
| Proceeds from the sale of equipment | 2,217 | 0 | 0 | 500 |
| Purchases of equipment | 983,257 | 933,156 | - | - |
| Purchases of investments | 139,262,781 | 12,043,721 | 129,868,915 | 122,924 |
| Proceeds from sales and maturities of investments | 74,596,145 | 11,270,722 | 0 | 9,991,364 |
| Net cash provided by (used in) investing activities | -65,647,676 | -1,706,155 | -129,868,915 | 9,868,940 |
| Proceeds from the 2025 pipe, net of series b issuance costs | - | 0 | 168,729,827 | - |
| Proceeds from the march 2026 public offering, net of issuance costs | 79,636,964 | - | - | - |
| Payment of deferred issuance costs | - | 758 | - | - |
| Proceeds from the march 2026 public offering underwriters option, net of issuance costs | 7,238,000 | - | - | - |
| Principal payments of notes payable | - | 0 | 3 | 275,846 |
| Proceeds from exercised warrants | 2,975,000 | - | - | - |
| Principal payments on finance leases | 37,388 | 36,675 | 35,977 | 69,911 |
| Proceeds from exercise of stock options | 113,116 | - | - | - |
| Tax payments for share settlement of restricted stock units | 4,571 | 4,252 | 4,881 | 2,072 |
| Net cash provided by (used in) financing activities | 89,921,121 | -41,685 | 168,688,966 | -347,829 |
| Effect of exchange rate changes on cash and cash equivalents | 14,729 | -397,861 | -37,537 | 221,901 |
| Net increase (decrease) in cash and cash equivalents | 10,017,044 | -18,922,028 | 25,732,491 | -5,205,749 |
| Beginning of period | 10,502,680 | -20,526,742 | 8,897,966 | - |
| End of period | 20,519,724 | -18,922,028 | 29,424,708 | - |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)